Literature DB >> 19164810

Vascular endothelial growth factor.

Napoleone Ferrara1.   

Abstract

Vascular endothelial growth factor (VEGF, VEGF-A) is a major regulator of physiological and pathological angiogenesis. Several VEGF inhibitors have been approved by the FDA for the treatment of advanced cancer and neovascular age-related macular degeneration. This brief review provides a historic account of the challenges associated with the discovery of VEGF and the early steps in elucidating the role of this molecule in the regulation of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164810     DOI: 10.1161/ATVBAHA.108.179663

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  157 in total

1.  Evolution of the VEGF-regulated vascular network from a neural guidance system.

Authors:  Sreenivasan Ponnambalam; Mario Alberghina
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

Review 2.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

3.  Effects of acid-base balance and high or low intensity exercise on VEGF and bFGF.

Authors:  Patrick Wahl; Christoph Zinner; Silvia Achtzehn; Michael Behringer; Wilhelm Bloch; Joachim Mester
Journal:  Eur J Appl Physiol       Date:  2010-12-15       Impact factor: 3.078

4.  Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.

Authors:  Napoleone Ferrara
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

5.  Angio-adaptation in unloaded skeletal muscle: new insights into an early and muscle type-specific dynamic process.

Authors:  Emilie Roudier; Charlotte Gineste; Alexandra Wazna; Kooroush Dehghan; Dominique Desplanches; Olivier Birot
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

6.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

7.  Competing endogenous RNA: A novel posttranscriptional regulatory dimension associated with the progression of cancer.

Authors:  Qingsong Dai; Jixia Li; Keyuan Zhou; Tong Liang
Journal:  Oncol Lett       Date:  2015-09-14       Impact factor: 2.967

8.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 9.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

10.  Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.

Authors:  Zanfeng Wang; Tingwei Liu
Journal:  Mol Cell Biochem       Date:  2017-08-31       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.